Volume 37, No. 10, page 5885 (only in the printed version): Abstract lines 11 to 17 should read:
vs. 46%, p=0.03), as did those who achieved disease control with pretreatments (61% vs. 35%, p<0.001). Bevacizumab-pretreated patients tended to show better objective response rates with nivolumab (23% vs. 13%, p=0.06); the objective response rate to nivolumab was significantly higher in bevacizumab-pretreated patients who showed clinical responses (38% vs. 8.9%, p=0.02). Conclusion: Achievement
- Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved